Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Biohaven Pharmaceutical stock in Canada

Biohaven Pharmaceutical stock has moved -0.18% from yesterday's closing price. Learn how to easily invest in Biohaven Pharmaceutical stock.

Biohaven Pharmaceutical is a biotechnology business based in the US. Biohaven Pharmaceutical stocks (BHVN.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $152.2 – an increase of 0.69% over the previous week. Biohaven Pharmaceutical employs 928 staff and has a trailing 12-month revenue of around $859.7 million.

How to buy stocks in Biohaven Pharmaceutical

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BHVN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Biohaven Pharmaceutical stock price (NYSE:BHVN)

Use our graph to track the performance of BHVN stocks over time.

Biohaven Pharmaceutical shares at a glance

Information last updated 2022-09-25.
Latest market close$152.20
52-week range$79.01 - $152.16
50-day moving average $148.37
200-day moving average $132.35
Wall St. target price$153.38
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-11.85

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$0 if conditions met, else $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
4.1 / 5
min $1.00, max 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends October 31, 2022.

Compare up to 4 providers

Is it a good time to buy Biohaven Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Biohaven Pharmaceutical price performance over time

Historical closes compared with the close of $152.2 from 2022-09-27

1 week (2022-09-21) 0.69%
1 month (2022-08-29) 2.37%
3 months (2022-06-29) 4.50%
6 months (2022-03-29) 25.12%
1 year (2021-09-29) 14.95%
2 years (2020-09-29) 140.98%
3 years (2019-09-27) 266.57%
5 years (2017-09-28) 300.53%

Biohaven Pharmaceutical financials

Revenue TTM $859.7 million
Gross profit TTM $370.8 million
Return on assets TTM -35.83%
Return on equity TTM 0%
Profit margin -118.82%
Book value $2.09
Market capitalisation $10.9 billion

TTM: trailing 12 months

Biohaven Pharmaceutical share dividends

We're not expecting Biohaven Pharmaceutical to pay a dividend over the next 12 months.

Biohaven Pharmaceutical share price volatility

Over the last 12 months, Biohaven Pharmaceutical's shares have ranged in value from as little as $79.01 up to $152.16. A popular way to gauge a stock's volatility is its "beta".

BHVN.US volatility(beta: 1.04)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Biohaven Pharmaceutical's is 1.0364. This would suggest that Biohaven Pharmaceutical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Biohaven Pharmaceutical overview

Biohaven Pharmaceutical Holding Company Ltd. , a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases. Its portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have four migraine attacks per month. It is also developing a pipeline of late-stage product candidates across five mechanistic platforms, including CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; MPO inhibition for amyotrophic lateral sclerosis; and Kv7 Ion Channel Activators (Kv7) for focal epilepsy and neuronal hyperexcitability, as well as myostatin inhibition for neuromuscular diseases. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site